|
Symbol
|
PMWLTQ | Z093XZ | OCJRCH | IHTEFG | HZJEFG | RMBFAV | OOIRCH | RLOALV | Z09YGZ | PBURCH | RMA3QV | RMBRKV | ERORCH | PEIRCH | ABMUTQ | PJIRCH | AZFBIL | PRZRCH | Z0ARNZ | CQWBKB |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nom | Multi Reverse Convertible | Autocallable Reverse Convertible Defensive worst | Worst of Callable Reverse Convertible | Reverse Convertible | Reverse Convertible | Multi Vonti | Worst of Callable Reverse Convertible | Reverse Convertible | Autocallable Reverse Convertible Defensive worst | Worst of Callable Reverse Convertible | Multi Vonti | Reverse Convertible | Worst of Callable Reverse Convertible | Worst of Callable Reverse Convertible | Multi Reverse Convertible | Worst of Callable Reverse Convertible | Reverse Convertible | Worst of Callable Reverse Convertible | Autocallable Reverse Convertible Defensive worst | Reverse Convertible |
|
Sous-jacent
|
Amgen Inc. / Lonza Group N / Novartis Sandoz Basket / Pfizer Inc. / Roche AG | Lonza Group N / Tecan Group AG / Ypsomed Hldg. AG | Kühne & Nagel Intl. AG / Lonza Group N / Sandoz Group AG | Compagnie Financière Richemont SA / Lonza Group N / Sonova Hldg. AG / Swiss RE AG / Swisscom N | Lonza Group N / Roche GS / Sika AG | Kühne & Nagel Intl. AG / Lonza Group N / Sika AG | Holcim/Amrize Basket / Kühne & Nagel Intl. AG / Lonza Group N / VAT Group | Lonza Group N | Compagnie Financière Richemont SA / Lonza Group N / Schindler PS / Sika AG | Alcon / Lonza Group N / Sandoz Group AG | Alcon / Lonza Group N / Novartis AG / Roche AG / Sandoz Group AG | Bucher Industries AG / Lonza Group N / Sika AG | BKW AG / Kühne & Nagel Intl. AG / Lonza Group N | Lonza Group N / Novartis AG / Roche AG / Sandoz | Clariant AG / Comet Hldg. AG / Lonza Group N / OC Oerlikon N / Swatch Group I | Bachem Hldg. AG / Lonza Group N / Ypsomed Hldg. AG | Companie Financière Richemont SA / Julius Baer Group / Lonza Group N | Lonza Group N / Swiss Life Hldg. N / Swiss RE AG | Holcim/Amrize Basket / Lonza Group N / Sandoz Group AG | Lonza Group N / Novartis N / Roche GS / Straumann Hldg. AG |
|
Emetteur
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Échéance
|
09.02.2026 | 19.02.2026 | 08.04.2026 | 28.06.2029 | 02.11.2026 | 13.07.2026 | 15.01.2026 | 30.12.2025 | 27.08.2027 | 21.07.2026 | 09.11.2026 | 05.11.2026 | 06.11.2026 | 11.11.2026 | 20.12.2029 | 16.06.2026 | 04.02.2026 | 24.02.2027 | 25.08.2026 | 13.03.2028 |
| Ratio | - | - | - | - | - | - | - | 0,09944 | - | - | - | - | - | - | - | - | - | - | - | - |
|
Prix d'exercise
|
218,09 | 274,88 | 20,8837 | 310,18 | 364,182 | 401,70 | 52,221 | 497,20 | 160,356 | 57,988 | 56,14 | 277,60 | 100,685 | 28,077 | 171,275 | 44,0525 | 447,90 | 97,965 | 33,0638 | 78,705 |
| rendement max. p.a. | - | 528,76% | 42,37% | - | - | 66,92% | 26,92% | - | 15,60% | 7,82% | 7,58% | 31,11% | 6,17% | 4,75% | 12,53% | 11,15% | 2,12% | 5,87% | 6,64% | 7,48% |
| Demande | - | - | - | - | 84,55 | 75,00 | 97,52 | 99,70 | - | - | 97,10 | 91,90 | - | 99,35 | 78,22 | 97,25 | 100,74 | 97,19 | - | 95,36 |
| Offre | - | - | - | - | - | 76,00 | 98,32 | 100,30 | - | - | 98,10 | 92,70 | - | 100,15 | 79,01 | 98,05 | 101,55 | 97,99 | - | 96,16 |